Latest News Archive

Please select Category, Year, and then Month to display items

UFS hosts launch of Khoebo Innovation Promotion Programme

14 November 2024 | Story André Damons | Photo André Damons

Khoebo Innovation Promotion Programme launch 2024 — Staff members from the Directorate Research Development (DRD) at the University of the Free State; Palesa Mgaga, second from right, Tebogo Machethe, centre, and Charelise van Staden, second from right, were thanked for hosting the launch of the Khoebo Innovation Promotion Programme. They are pictured with colleagues from the IDC’s Samkelisiwe Mtsewu, left, and Thato Mogopodi, far right.

The University of the Free State (UFS), represented by the Directorate Research Development (DRD), played host to the Department of Trade Industry and Competition (dtic) and the Industrial Development Corporation (IDC) for the launch of its Khoebo Innovation Promotion Programme (KIPP).

The launch took place on 5 November in the Sasol Library on the Bloemfontein Campus. Tebogo Machethe, Director: Research Contracts and Innovation at the DRD, said its role was to expose the university researchers to different opportunities and programmes for funding from the IDC and the dtic. It also allowed the researchers to engage potential funders in order to understand what funders look for in a project when considering funding it.

“The aim of IDC KIPP is to assist local entrepreneurs and small to medium enterprises with commercialisation funding. The KIPP offers capital and business support to SMMEs during the early stages of commercialisation with particular emphasis on township and rural entrepreneurs,” said Machethe.

Address uneven distribution of economic development

KIPP is a dtic programme but is managed by the IDC and aims to enable early-stage innovative SMEs to penetrate the market with their locally developed innovations, resulting in a more competitive economic environment and thereby facilitating economic growth in the economy.

According to Machethe, who welcomed the guests, participants and presenters to the launch, some of the funding is geared towards the development of university innovations. Though the focus was on the KIPP launch, he continued, the discussions also encompassed other forms of funding that are available and more geared towards the university innovation.

His address was centred around the university's Vision 130 and how it supports innovation and the entire innovation ecosystem, which seeks to shift the emphasis to research impact, embracing both knowledge and societal impact. Vision 130 identifies the need for a greater focus on collaborative research, research that can attract large-scale funding in niche areas where the university is seen as a national and global leader.

Samkelisiwe Mtsewu, KIPP Account Manager at the IDC, said the programme was introduced to address the uneven distribution of economic development across the country. She said with its capacity, the KIPP programme can contribute to addressing the uneven distribution of economic development.

News Archive

New research informs improved treatment of brain inflammation

2017-10-13

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish

Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology.

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs.

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept